{"success":true,"data":{"pressRelease":{"id":"109943","rtpr_id":"nGNX4Srl03","ticker":"WW","exchange":"NASDAQ","all_tickers":["WW"],"title":"Weight Watchers Announces Second Quarter 2026 Results","author":"Globe Newswire","published_at":"2026-08-05T20:01:03.989Z","article_body":"Total End of Period Subscribers of 2.5 million; End of Period Clinical\nSubscribers of 197 thousand, up 55.7% year-over-year\n\nCore+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year,\nreflecting third consecutive quarter of sequential growth\n\nRevenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up\n30.4% year-over-year\n\nReaffirms Full Year 2026 Financial Guidance\n\nNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq:\nWW) (“Weight Watchers” or the “Company”), the global leader in\nscience-backed weight management, today announced its results for the second\nquarter of 2026 ended June 30, 2026(1) in this Earnings Press Release and a\nShareholder Letter issued today and posted on the Company’s Corporate\nWebsite.\n\n“We view 2026 as a year of focused transition for Weight Watchers, and our\nQ2 results reflect that work taking hold across the business,” said Jon\nVolkmann, Chief Operations Officer and member of the Company’s Interim\nOffice of the Chief Executive. “Core+, our high-value Behavioral tier\ndelivering tailored expert coaching and integrated weight health support,\nposted sequential subscriber growth for the third consecutive quarter,\nunderscoring that members continue to embrace our holistic approach.”\n\n“We are pleased with the continued momentum in Core+, which saw subscriber\ncount grow 13.9% year-over-year and represents a clear signal that interest in\nour Behavioral business is stabilizing while our Clinical business continues\nto grow,” said Felicia DellaFortuna, Chief Financial Officer and member of\nthe Company’s Interim Office of the Chief Executive. “End of Period\nClinical Subscribers grew 55.7% year-over-year, and the sequential stability\nwe saw in subscribers from Q1 to Q2 2026 reflects a deliberate recalibration\nof marketing investment following elevated peak season spend. We are\nreaffirming our full-year 2026 Revenue and Adjusted EBITDA(2) guidance. With a\nbusiness that remains cash accretive and generated positive operating cash\nflow in Q2, we have confidence in our ability to continue building momentum\ninto 2027 and beyond.”\n\nQ2 Business Updates\n* Q2 2026 Clinical Subscription Revenue grew 30.4% year-over-year and End of\nPeriod Clinical Subscribers grew 55.7% year-over-year, despite lapping\nsignificant prior-year growth in Q2 2025 from the Company’s former\ncompounded semaglutide offering. End of Period Clinical Subscribers were flat\ncompared to Q1 2026, as the Company strategically recalibrated its Clinical\nmarketing investment following elevated spend in Q1 2026.\n* Core+ represented 541 thousand End of Period Subscribers at the end of Q2\n2026, up 13.9% from Q2 2025, representing the third consecutive quarter of\nsequential growth in the Company’s higher-value Behavioral tier.\n* Q2 Monthly Subscription Revenue Per Average Subscriber (ARPU) increased\n10.2% year-over-year, driven by the continued mix shift towards Clinical.\n* Q2 Gross Margin was 70.3%. Q2 Adjusted Gross Margin(2) was 73.6%, which\nremained near record highs, reflecting continued operational discipline across\nthe Company’s portfolio.\n* Marketing expense was $47.9 million or 29.5% of Revenue, declining from\n$92.9 million in Q1 2026 as the Company moved past peak season and rebalanced\ninvestment across its business lines.\n* Q2 Net Income was $14.1 million, which reflects higher depreciation and\namortization related to Fresh Start Accounting(1). Q2 Adjusted EBITDA(2) was\n$39.8 million.\nBalance Sheet and Liquidity Updates\n* Cash and Cash Equivalents balance as of June 30, 2026 was $101.5 million.\n* Operating activities generated $24.3 million of cash in Q2 2026, reflecting\nthe cash-generative nature of the Weight Watchers business and continued\ncommitment to maintaining a strong liquidity position as the Company executes\nits strategic priorities.\n* In Q2 2026, the Company prepaid $36.8 million in cash to reduce the\nprincipal amount of its outstanding term loan. The prepayment was comprised of\nthe following two components: * In June 2026, $26.8 million in aggregate\nprincipal amount of prepayment from the annual cash sweep; and\n* In May 2026, $10.0 million as part of the voluntary solicitation, which was\nfully subscribed at 68.5% of par.\nAs a result of these actions, the Company reduced the aggregate principal\namount of its outstanding term loan by $41.4 million and reduced its\nannualized interest expense by approximately $4 million(3).\n\n2026 Guidance\n\nThe Company reaffirms its previously provided guidance for the year ending\nDecember 31, 2026.\n* Revenue guidance of $620 million to $635 million.\n* Adjusted EBITDA(2) guidance of $105 million to $115 million.\nSecond Quarter 2026 Conference Call and Webcast\n\nThe Company has scheduled a conference call today at 5:00 p.m. ET to discuss\nresults. The webcast of the conference call will be available on the\nCompany’s corporate website, corporate.ww.com, under Events and\nPresentations. A replay of the webcast will be available on this site for at\nleast 90 days.\n\n(1)Fresh Start Accounting and Predecessor and Successor Periods\n\nIn connection with the Company’s emergence from its financial reorganization\nprocess on June 24, 2025, the Company applied fresh start accounting which\nresulted in Successor and Predecessor financial statement presentation.\nReferences to “Successor” relate to the Company’s operations for the\nthree and six months ended June 30, 2026 and the period from June 25, 2025\nthrough December 31, 2025. References to “Predecessor” relate to the\nCompany’s operations for the periods from March 30, 2025 through June 24,\n2025 and December 29, 2024 through June 24, 2025. Accordingly, the\nconsolidated financial statements after June 24, 2025 are not comparable with\nthe consolidated financial statements as of or prior to that date.\n\n(2)Statement regarding Non-GAAP Financial Measures\n\nTo supplement the Company’s consolidated results presented in accordance\nwith accounting principles generally accepted in the United States\n(“GAAP”), the Company has disclosed non-GAAP financial measures of\noperating results that exclude or adjust certain items. The Company presents\nin this release non-GAAP financial measures, including earnings before\ninterest, taxes, depreciation and amortization expenses and share-based\ncompensation expense (“EBITDA”); and for each period presented, EBITDA\nadjusted, as applicable, for (a) goodwill and other indefinite-lived\nintangible asset impairments, (b) reorganization items, net related to the\nCompany’s emergence from its Chapter 11 financial reorganization, (c) gain\non extinguishment of debt, (d) transaction costs related to strategic\nalternatives and the Company’s Chapter 11 financial reorganization, (e) net\nrestructuring charges associated with the previously disclosed 2025, 2024, and\n2023 restructuring plans, (f) non-recurring expenses in connection with the\nmanagement of certain executive matters, and (g) other items such as the\nimpact of foreign exchange gains and losses as indicated in the\nreconciliations below that management believes are not indicative of ongoing\noperations (“Adjusted EBITDA”). The Company also presents gross profit,\ngross margin, marketing expenses, selling, general and administrative\nexpenses, and product development expenses on a non-GAAP basis that adjusts\nfor similar items, as further indicated in the reconciliations below.\n\nAs exchange rates are an important factor in understanding period-to-period\ncomparisons, the Company believes in certain cases the presentation of results\non a constant currency basis in addition to reported results helps improve\ninvestors’ ability to understand the Company’s operating results and\nevaluate the Company’s performance in comparison to prior periods. Constant\ncurrency information compares results between periods as if exchange rates had\nremained constant period-over-period. The Company uses results on a constant\ncurrency basis as one measure to evaluate the Company’s performance. In this\npress release, the Company calculates constant currency by calculating\ncurrent-year results using prior-year foreign currency exchange rates. The\nCompany generally refers to such amounts calculated on a constant currency\nbasis as excluding or adjusting for the impact of foreign currency or being on\na constant currency basis. These results should be considered in addition to,\nnot as a substitute for, results reported in accordance with GAAP and are not\nmeant to be considered in isolation. Results on a constant currency basis, as\nthe Company presents them, may not be comparable to similarly titled measures\nused by other companies and are not measures of performance presented in\naccordance with GAAP.\n\nManagement believes these non-GAAP financial measures provide useful\nsupplemental information to investors regarding the performance of the\nCompany’s business and are useful for period-over-period comparisons of the\nperformance of the Company’s business. While the Company believes that these\nnon-GAAP financial measures are useful in evaluating the Company’s business,\nthis information should be considered as supplemental in nature and is not\nmeant to be considered in isolation or as a substitute for the related\nfinancial information prepared in accordance with GAAP. In addition, these\nnon-GAAP financial measures may not be the same as similarly titled measures\nreported by other companies. See “Reconciliation of Non-GAAP Financial\nMeasures” in this release and reconciliations, if any, included elsewhere in\nthis release for a reconciliation of the non-GAAP financial measures to the\nmost directly comparable GAAP measures.\n\nA reconciliation of the forward-looking full year Adjusted EBITDA outlook to\nnet income cannot be provided without unreasonable effort because of the\ninherent difficulty of accurately forecasting the occurrence and financial\nimpact of the various adjusting items necessary for such reconciliation that\nhave not yet occurred, are out of the Company’s control, or cannot be\nreasonably predicted. For the same reasons, the Company is unable to assess\nthe probable significance of the unavailable information, which could have a\nmaterial impact on its future GAAP financial results.\n\n(3)The interest rate in effect for the term loan as of June 30, 2026 was\n10.53%.\n\nDefinitions\n\n“Behavioral” business refers to providing subscriptions to the Company’s\ndigital product offerings with the option to add on unlimited access to the\nCompany’s workshops.\n\n“Clinical” business refers to providing subscriptions to the Company’s\nclinical product offerings provided by Weight Watchers Clinic and third\nparties combined with the Company’s digital subscription product offerings\nand unlimited access to the Company’s workshops.\n\n“Revenue” - “Subscription Revenue” consists of the aggregate of: (a)\n“Behavioral Subscription Revenue”, the fees associated with subscriptions\nfor the Company’s Behavioral offerings; and (b) “Clinical Subscription\nRevenue”, the fees associated with subscriptions for the Company’s\nClinical offerings. In addition, “Other Revenue” consists of revenue from\nlicensing, franchise fees with respect to commitment plans and royalties,\npublishing and other revenue. “Revenue” consists of the aggregate of\nSubscription Revenue and Other Revenue.\n\n“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers\nand Clinical subscribers who participate in recurring bill programs in\nCompany-owned operations. The “Incoming Subscribers” metric reports\nSubscribers in Company-owned operations at a given period start. Recruitment\nand retention are key drivers for this metric. Management utilizes this metric\nto monitor changes in the subscriber base which directly impacts the\nCompany’s revenue growth and trends.\n\n“End of Period Subscribers” - The “End of Period Subscribers” metric\nreports Subscribers in Company-owned operations at a given period end.\nRecruitment and retention are key drivers for this metric. Management utilizes\nthis metric to monitor changes in the subscriber base which directly impacts\nthe Company’s revenue growth and trends.\n\n“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The\n“Monthly Subscription Revenue Per Average Subscriber” metric reports the\nmonthly fees associated with subscriptions for the Company’s offerings\ndivided by the Average Subscriber for its businesses. Monthly Subscription\nRevenue for both quarterly and year-to-date periods for each respective\nbusiness are calculated as Subscription Revenue divided by the number of\nmonths in the respective quarterly or year-to-date period. The “Average\nSubscriber” for quarterly periods for each respective business is the\naverage of its Incoming Subscribers and End of Period Subscribers for the\nrespective quarterly period. The “Average Subscriber” for year-to-date\nperiods for each respective business is the average of its Incoming\nSubscribers at the beginning of the fiscal year and its End of Period\nSubscribers for each quarter end within the respective year-to-date period.\nManagement utilizes this metric to consider revenue growth and trends on a per\nsubscriber basis.\n\nAbout Weight Watchers\nWeight Watchers is the global leader in science-backed weight management,\noffering an integrated support system built for the GLP-1 era that combines\nscientific expertise, medication, cutting-edge technology, and human\nconnection. With more than 60 years of experience, Weight Watchers is the most\nstudied commercial weight management program in the world, delivered through\nits No. 1 U.S. doctor-recommended weight-loss program. Its holistic,\npersonalized approach also includes U.S.-based clinical interventions and\naccess to GLP-1 medications when clinically appropriate, and a global network\nof coaches and community support. Since 1963, the company has led with science\nto deliver its members the personalized support they need to reach and sustain\ntheir goals. Members can access these solutions directly, or through Weight\nWatchers for Business’ full-spectrum platform for employers, health plans,\nand payers. In a landscape crowded with contradictory advice, isolating apps,\nand one-size-fits-all solutions, Weight Watchers offers a proven path forward\nthat is rooted in research, grounded in empathy and designed to help every\nmember feel better in their body and live a longer, healthier life. For more\ninformation, visit weightwatchers.com.\n\nThis press release includes “forward-looking statements,” within the\nmeaning of Section 27A of the Securities Act of 1933, as amended, and Section\n21E of the Securities Exchange Act of 1934, as amended, including, in\nparticular, any statements about the Company’s plans, strategies,\nobjectives, initiatives, and prospects. The Company generally uses the words\n“may,” “will,” “could,” “expect,” “anticipate,”\n“believe,” “estimate,” “plan,” “intend,” “aim” and similar\nexpressions in this press release to identify forward-looking statements. The\nCompany bases these forward-looking statements on its current views with\nrespect to future events and financial performance. Actual results could\ndiffer materially from those projected in the forward-looking statements.\nThese forward-looking statements are subject to risks, uncertainties and\nassumptions, including, among other things: the Company's recent emergence\nfrom bankruptcy, which could adversely affect its business and relationships\nand subjects us to risks and uncertainties; competition from other weight\nmanagement and health and wellness industry participants or the development of\nmore effective or more favorably perceived weight management methods; the\nCompany's failure to continue to retain and grow its subscriber base; the\nCompany's ability to be a leader in the rapidly evolving and increasingly\ncompetitive clinical weight management and weight loss market; the Company's\nability to continue to develop new, innovative services and products and\nenhance its existing services and products or the failure of its services,\nproducts or brands to continue to appeal to the market, or its ability to\nsuccessfully expand into new channels of distribution or respond to consumer\ntrends or sentiment; the Company's ability to successfully implement strategic\ninitiatives; the effectiveness and efficiency of its advertising and marketing\nprograms across multiple platforms, including digital marketing and social\nmedia platforms; the impact on the Company's reputation of actions taken by\nits franchisees, licensees, suppliers, affiliated provider entities, PCs’\nhealthcare professionals, and other partners; the recognition of asset\nimpairment charges; the loss of key personnel, strategic partners or\nconsultants or failure to effectively manage and motivate the Company's\nworkforce; the Company’s chief executive officer transition, and its ability\nto appoint a new chief executive officer with the required level of experience\nand expertise in a timely manner; the Company's ability to successfully make\nacquisitions or enter into collaborations or joint ventures, including its\nability to successfully integrate, operate or realize the anticipated benefits\nof such businesses; uncertainties related to a downturn in general economic\nconditions or consumer confidence, including as a result of the existing\ninflationary environment, changes in tariffs and escalating trade tensions,\nrising interest rates, the potential impact of political and social unrest and\nincreased volatility in the credit and capital markets; the seasonal nature of\nthe Company's business; the Company's failure to maintain effective internal\ncontrol over financial reporting; the impact of events that impede accessing\nresources or discourage or impede people from gathering with others; the early\ntermination by us of leases; the inability to renew certain of the Company's\nlicenses, or the inability to do so on terms that are favorable to us; the\ndependence of the Company's payments system on third-party service providers;\nthe impact of the Company's exposure to variable rate indebtedness; the\nability to generate sufficient cash to service the Company's debt and satisfy\nits other liquidity requirements; uncertainties regarding the satisfactory\noperation of the Company's technology or systems; the impact of data security\nbreaches and other malicious acts or privacy concerns, including the costs of\ncompliance with evolving privacy laws and regulations; the Company's ability\nto successfully integrate and use artificial intelligence in its business; the\nCompany's ability to enforce its intellectual property rights both\ndomestically and internationally, as well as the impact of its involvement in\nany claims related to intellectual property rights; the impact of existing and\nfuture laws and regulations; risks related to the Company's exposure to\nextensive and complex healthcare laws and regulations; the outcomes of\nlitigation or regulatory actions; risks and uncertainties associated with the\nCompany's international operations, including regulatory, economic, political,\nsocial, intellectual property, and foreign currency risks, which risks may be\nexacerbated as a result of war and terrorism; the Company's ability to engage\nin share repurchases and pay cash dividends in the foreseeable future; risks\nrelated to the actions of activist shareholders and anti-takeover provisions\nin the Company's articles of incorporation and bylaws; risks related to the\nactions of the Company's shareholders and the exclusive forum provisions in\nits articles of incorporation; the possibility that the Company could fail to\nmaintain the listing of the Company's common stock on Nasdaq; and other risks\nand uncertainties, including those included in this press release and those\ndetailed from time to time in the Company’s periodic reports filed with the\nSecurities and Exchange Commission (the “SEC”) (which are available on the\nSEC’s EDGAR database at www.sec.gov and via the Company’s website at\ncorporate.ww.com). You should not put undue reliance on any forward-looking\nstatements. You should understand that many important factors, including those\ndiscussed herein, could cause the Company’s results to differ materially\nfrom those expressed or suggested in any forward-looking statement. Except as\nrequired by law, the Company does not undertake any obligation to update or\nrevise these forward-looking statements to reflect new information or events\nor circumstances that occur after the date of this press release or to reflect\nthe occurrence of unanticipated events or otherwise. Readers are advised to\nreview the Company’s filings with the SEC (which are available on the\nSEC’s EDGAR database at www.sec.gov and via the Company’s website at\ncorporate.ww.com).\n\nFor investor inquiries, please contact:\nAnna Kate Heller \nWeightWatchers@icrinc.com\n\nFor media inquiries, please contact:\nMelissa Garbayo\nmelissa.garbayo@ww.com\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED BALANCE SHEETS \n (IN THOUSANDS) \n UNAUDITED \n \n Successor \n June 30, December 31, \n 2026 2025 \n ASSETS \n CURRENT ASSETS \n Cash and cash equivalents $ 101,497 $ 160,279 \n Restricted cash 5,796 6,298 \n Receivables (net of allowances: June 30, 2026 - $1,985 and December 31, 2025 - $1,651) 15,923 16,378 \n Prepaid income taxes 6,573 8,097 \n Prepaid marketing and advertising 3,079 9,275 \n Prepaid expenses and other current assets 14,017 13,277 \n TOTAL CURRENT ASSETS 146,885 213,604 \n Property and equipment, net 6,886 8,115 \n Operating lease assets 2,148 2,933 \n Goodwill 199,910 200,135 \n Other intangible assets, net 453,289 490,664 \n Deferred income taxes 16,068 16,482 \n Other noncurrent assets 15,256 14,825 \n TOTAL ASSETS $ 840,442 $ 946,758 \n LIABILITIES AND EQUITY \n CURRENT LIABILITIES \n Portion of operating lease liabilities due within one year $ 991 $ 1,260 \n Accounts payable 22,537 9,212 \n Salaries and wages payable 20,366 34,375 \n Accrued marketing and advertising 12,238 22,985 \n Accrued interest 867 1,084 \n Other accrued liabilities 21,527 23,049 \n Income taxes payable 2,333 6,006 \n Deferred revenue 25,215 28,565 \n TOTAL CURRENT LIABILITIES 106,074 126,536 \n Long-term debt, net 423,995 465,466 \n Long-term operating lease liabilities 1,325 1,893 \n Deferred income taxes 29,858 34,021 \n Other noncurrent liabilities 540 771 \n TOTAL LIABILITIES 561,792 628,687 \n EQUITY \n Successor common stock, $0 par value; 1,000,000 shares authorized; 9.999 shares issued at June 30, 2026 and 9,992 shares issued at December 31, 2025 379,690 378,777 \n Accumulated deficit (100,021 ) (62,095 ) \n Accumulated other comprehensive (loss) income (1,019 ) 1,389 \n TOTAL EQUITY 278,650 318,071 \n TOTAL LIABILITIES AND TOTAL EQUITY $ 840,442 $ 946,758 \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF OPERATIONS \n (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) \n UNAUDITED \n \n Successor Predecessor \n Three Months Ended Period from Period from \n June 30, 2026 June 25, 2025 March 30, 2025 \n through June 30, 2025 through June 24, 2025 \n \n \n Subscription revenue, net ((1)) $ 161,392 $ 12,078 $ 175,773 \n Other revenue, net ((2)) 932 89 1,224 \n Revenue, net 162,324 12,167 176,997 \n Cost of subscription revenue ((3)) 48,015 3,258 46,439 \n Cost of other revenue 167 — 50 \n Cost of revenue 48,182 3,258 46,489 \n Gross profit 114,142 8,909 130,508 \n Marketing expenses 47,875 2,784 32,093 \n Product development expenses 6,441 686 14,160 \n Selling, general and administrative expenses 50,352 2,853 42,851 \n Operating income 9,474 2,586 41,404 \n Reorganization items, net — — (1,143,918 ) \n Interest expense 11,588 923 11,061 \n Gain on extinguishment of debt (4,612 ) — — \n Other (income) expense, net (421 ) 932 4,478 \n Income before income taxes 2,919 731 1,169,782 \n Benefit from income taxes (11,155 ) (523 ) (20,906 ) \n Net income $ 14,074 $ 1,254 $ 1,190,688 \n \n Earnings per share \n Basic $ 1.41 $ 0.13 $ 14.81 \n Diluted $ 1.41 $ 0.13 $ 14.67 \n \n Weighted average common shares outstanding \n Basic 9,999 9,987 80,419 \n Diluted 10,001 9,987 81,165 \n \n \n Note: Totals may not sum due to rounding. \n ((1) )“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. \n ((2))“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n ((3))“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF OPERATIONS \n (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) \n UNAUDITED \n \n Successor Predecessor \n Six Months Ended Period from Period from \n June 30, 2026 June 25, 2025 December 29, 2024 \n through June 30, 2025 through June 24, 2025 \n \n \n Subscription revenue, net ((1)) $ 328,749 $ 12,078 $ 360,953 \n Other revenue, net ((2)) 1,836 89 2,615 \n Revenue, net 330,585 12,167 363,568 \n Cost of subscription revenue ((3)) 97,460 3,258 100,026 \n Cost of other revenue 310 — 158 \n Cost of revenue 97,770 3,258 100,184 \n Gross profit 232,815 8,909 263,384 \n Marketing expenses 140,809 2,784 110,871 \n Product development expenses 14,534 686 25,281 \n Selling, general and administrative expenses 98,436 2,853 78,480 \n Franchise rights acquired impairments — — 27,549 \n Operating (loss) income (20,964 ) 2,586 21,203 \n Reorganization items, net — — (1,143,918 ) \n Interest expense 23,064 923 38,664 \n Gain on extinguishment of debt (4,612 ) — — \n Other (income) expense, net (1,158 ) 932 6,685 \n (Loss) income before income taxes (38,258 ) 731 1,119,772 \n (Benefit from) provision for income taxes (332 ) (523 ) 1,669 \n Net (loss) income $ (37,926 ) $ 1,254 $ 1,118,103 \n \n (Net loss) earnings per share \n Basic $ (3.79 ) $ 0.13 $ 13.93 \n Diluted $ (3.79 ) $ 0.13 $ 13.80 \n \n Weighted average common shares outstanding \n Basic 9,998 9,987 80,271 \n Diluted 9,998 9,987 80,998 \n \n \n Note: Totals may not sum due to rounding. \n ((1) )“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. \n ((2))“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n ((3))“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF CASH FLOWS \n (IN THOUSANDS) \n UNAUDITED \n \n Successor Predecessor \n Six Months Ended Period from Period from \n June 30, 2026 June 25, 2025 December 29, 2024 \n through June 30, 2025 through June 24, 2025 \n \n \n Operating activities: \n Net (loss) income $ (37,926 ) $ 1,254 $ 1,118,103 \n Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities: \n Depreciation and amortization 51,802 1,681 14,201 \n Amortization of deferred financing costs and debt (premium) discount, net (51 ) — 1,766 \n Impairment of franchise rights acquired — — 27,549 \n Impairment of intangible and long-lived assets 3 — 97 \n Share-based compensation expense 840 — 4,032 \n Deferred tax (benefit) provision (4,259 ) — 26,232 \n Allowance for doubtful accounts 27 — (1,131 ) \n Foreign currency exchange rate (gain) loss (1,059 ) 933 6,717 \n Non-cash reorganization items, net — — (1,176,532 ) \n Gain on extinguishment of debt (4,612 ) — — \n Changes in cash due to: \n Receivables 227 466 4,280 \n Prepaid expenses 6,978 586 (31,281 ) \n Accounts payable 12,357 406 (8,237 ) \n Accrued liabilities (26,171 ) 6,178 15,084 \n Deferred revenue (3,178 ) 47 (2,914 ) \n Other long term assets and liabilities, net (599 ) — (2,234 ) \n Income taxes (3,654 ) (43 ) (30,155 ) \n Cash (used for) provided by operating activities (9,275 ) 11,508 (34,423 ) \n Investing activities: \n Capital expenditures — — (87 ) \n Capitalized software and website development expenditures (11,935 ) (188 ) (6,253 ) \n Other items, net — — (1 ) \n Cash used for investing activities (11,935 ) (188 ) (6,341 ) \n Financing activities: \n Borrowings on revolving credit facility — — 171,341 \n Financing costs — — (1,298 ) \n Payments on long-term debt (36,808 ) — — \n Taxes paid related to net share settlement of equity awards — — (145 ) \n Cash paid for acquisitions — — (16,000 ) \n Cash (used for) provided by financing activities (36,808 ) — 153,898 \n Effect of exchange rate changes on cash and cash equivalents and restricted cash (1,266 ) 544 3,966 \n Net (decrease) increase in cash and cash equivalents and restricted cash (59,284 ) 11,864 117,100 \n Cash and cash equivalents and restricted cash, beginning of period 166,577 173,620 56,520 \n Cash and cash equivalents and restricted cash, end of period $ 107,293 $ 185,484 $ 173,620 \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Variance \n Successor 2026 vs 2025 Combined 2026 Constant Currency vs 2025 Combined \n Three Months Ended Three Months Ended \n June 30, 2026 June 30, 2025 \n GAAP Constant Currency Combined ((1)) \n \n Selected Financial Data \n Revenue ((2)) $ 162,324 $ 161,523 $ 189,163 (14.2 %) (14.6 %) \n Behavioral Subscription Revenue ((3)) $ 121,486 $ 120,689 $ 157,258 (22.7 %) (23.3 %) \n Clinical Subscription Revenue ((4)) $ 39,906 $ 39,908 $ 30,593 30.4 % 30.4 % \n Subscription Revenue ((5)) $ 161,392 $ 160,597 $ 187,851 (14.1 %) (14.5 %) \n Other Revenue ((6)) $ 932 $ 926 $ 1,312 (29.0 %) (29.4 %) \n \n \n Note: Totals may not sum due to rounding. \n ((1))These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented. \n ((2))“Revenue” consists of the aggregate of Subscription Revenue and Other Revenue. \n ((3))“Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings. \n ((4))“Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings. \n ((5))“Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue. \n ((6))“Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Variance \n Successor 2026 vs 2025 Combined 2026 Constant Currency vs 2025 Combined \n Six Months Ended June 30, 2026 Six Months Ended June 30, 2025 \n GAAP Constant Currency Combined ((1)) \n \n Selected Financial Data \n Revenue ((2)) $ 330,585 $ 325,531 $ 375,735 (12.0 %) (13.4 %) \n Behavioral Subscription Revenue ((3)) $ 250,010 $ 245,006 $ 312,981 (20.1 %) (21.7 %) \n Clinical Subscription Revenue ((4)) $ 78,739 $ 78,741 $ 60,051 31.1 % 31.1 % \n Subscription Revenue ((5)) $ 328,749 $ 323,746 $ 373,032 (11.9 %) (13.2 %) \n Other Revenue ((6)) $ 1,836 $ 1,784 $ 2,703 (32.1 %) (34.0 %) \n \n \n Note: Totals may not sum due to rounding. \n ((1))These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented. \n ((2))“Revenue” consists of the aggregate of Subscription Revenue and Other Revenue. \n ((3))“Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings. \n ((4))“Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings. \n ((5))“Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue. \n ((6))“Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n OPERATIONAL STATISTICS \n (IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER) \n UNAUDITED \n \n Successor Combined \n Three Months Ended Three Months Ended \n June 30, 2026 June 30, 2025 Variance Variance \n (Constant Currency) (Constant Currency) \n Incoming Subscribers ((1)) \n Incoming Behavioral Subscribers 2,463 N/A 3,299 (25.4 %) N/A \n Incoming Clinical Subscribers 197 N/A 135 45.9 % N/A \n Incoming Subscribers 2,659 N/A 3,434 (22.6 %) N/A \n \n End of Period Subscribers ((2)) \n End of Period Behavioral Subscribers 2,291 N/A 3,040 (24.6 %) N/A \n End of Period Clinical Subscribers 197 N/A 127 55.7 % N/A \n End of Period Subscribers 2,489 N/A 3,167 (21.4 %) N/A \n \n Monthly Subscription Revenue Per Average Subscriber ( (3)) \n Monthly Behavioral Subscription Revenue Per Average Subscriber $ 17.04 $ 16.92 $ 16.54 3.0 % 2.3 % \n Monthly Clinical Subscription Revenue Per Average Subscriber $ 67.55 $ 67.55 $ 78.00 (13.4 %) (13.4 %) \n Monthly Subscription Revenue Per Average Subscriber $ 20.90 $ 20.80 $ 18.97 10.2 % 9.6 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start. \n ((2))The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end. \n ((3))The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers \n and End of Period Subscribers for the respective quarterly period. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n OPERATIONAL STATISTICS \n (IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER) \n UNAUDITED \n \n Successor Combined \n Six Months Ended Six Months Ended \n June 30, 2026 June 30, 2025 Variance Variance \n (Constant Currency) (Constant Currency) \n Incoming Subscribers ((1)) \n Incoming Behavioral Subscribers 2,631 N/A 3,244 (18.9 %) N/A \n Incoming Clinical Subscribers 130 N/A 92 41.9 % N/A \n Incoming Subscribers 2,761 N/A 3,336 (17.2 %) N/A \n \n End of Period Subscribers ((2)) \n End of Period Behavioral Subscribers 2,291 N/A 3,040 (24.6 %) N/A \n End of Period Clinical Subscribers 197 N/A 127 55.7 % N/A \n End of Period Subscribers 2,489 N/A 3,167 (21.4 %) N/A \n \n Monthly Subscription Revenue Per Average Subscriber ( (3)) \n Monthly Behavioral Subscription Revenue Per Average Subscriber $ 16.91 $ 16.57 $ 16.33 3.6 % 1.5 % \n Monthly Clinical Subscription Revenue Per Average Subscriber $ 75.13 $ 75.13 $ 85.01 (11.6 %) (11.6 %) \n Monthly Subscription Revenue Per Average Subscriber $ 20.76 $ 20.45 $ 18.77 10.6 % 8.9 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start. \n ((2))The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end. \n ((3))The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective year-to-date period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming \n Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Period from Period from \n Three Months Ended June 25, 2025 March 30, 2025 \n June 30, 2026 through June 30, 2025 through June 24, 2025 \n Selling, Selling, Selling, \n Product General, and Product General, and Product General, and \n Gross Marketing Development Administrative Gross Marketing Development Administrative Gross Marketing Development Administrative \n Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses \n \n GAAP $ 114,142 $ 47,875 $ 6,441 $ 50,352 $ 8,909 $ 2,784 $ 686 $ 2,853 $ 130,508 $ 32,093 $ 14,160 $ 42,851 \n % of Revenue 70.3 % 29.5 % 4.0 % 31.0 % 73.2 % 22.9 % 5.6 % 23.4 % 73.7 % 18.1 % 8.0 % 24.2 % \n \n Adjustments: \n Transaction Costs ((1)) $ — $ — $ — $ — $ — $ — $ — $ (182 ) $ — $ — $ — $ (10,049 ) \n Depreciation and Amortization Expenses 5,331 — — (20,585 ) 330 — (4 ) (1,347 ) 4,147 — (54 ) (3,086 ) \n Restructuring Charges ((2)) — — — 156 — — — — (2,071 ) — — (977 ) \n Share-based Compensation Expense 0 (160 ) (109 ) (463 ) — — — — — — — (3,171 ) \n Executive Related One-Time Costs ((3)) — — — (3,798 ) — — — — — — — — \n Total Adjustments $ 5,332 $ (160 ) $ (109 ) $ (24,690 ) $ 330 $ — $ (4 ) $ (1,529 ) $ 2,076 $ — $ (54 ) $ (17,284 ) \n \n Adjusted $ 119,474 $ 47,715 $ 6,332 $ 25,662 $ 9,239 $ 2,784 $ 682 $ 1,324 $ 132,584 $ 32,093 $ 14,106 $ 25,567 \n % of Revenue 73.6 % 29.4 % 3.9 % 15.8 % 75.9 % 22.9 % 5.6 % 10.9 % 74.9 % 18.1 % 8.0 % 14.4 % \n \n Currency Adjustment (698 ) (41 ) 0 (51 ) N/A N/A N/A N/A N/A N/A N/A N/A \n \n Constant Currency $ 113,444 $ 47,834 $ 6,441 $ 50,301 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 70.2 % 29.6 % 4.0 % 31.1 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n Adjusted Constant Currency $ 118,775 $ 47,675 $ 6,332 $ 25,610 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 73.5 % 29.5 % 3.9 % 15.9 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n \n Note: Totals may not sum due to rounding. \n ((1))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((2))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((3))Non-recurring expenses in connection with the management of certain executive matters. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Period from Period from \n Six Months Ended June 25, 2025 December 29, 2024 \n June 30, 2026 through June 30, 2025 through June 24, 2025 \n Selling, Selling, Selling, \n Product General, and Product General, and Product General, and \n Gross Marketing Development Administrative Gross Marketing Development Administrative Gross Marketing Development Administrative \n Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses \n \n GAAP $ 232,815 $ 140,809 $ 14,534 $ 98,436 $ 8,909 $ 2,784 $ 686 $ 2,853 $ 263,384 $ 110,871 $ 25,281 $ 78,480 \n % of Revenue 70.4 % 42.6 % 4.4 % 29.8 % 73.2 % 22.9 % 5.6 % 23.4 % 72.4 % 30.5 % 7.0 % 21.6 % \n \n Adjustments: \n Transaction Costs ((1)) $ — $ — $ — $ — $ — $ — $ — $ (182 ) $ — $ — $ — $ (20,873 ) \n Depreciation and Amortization Expenses 10,512 — — (41,290 ) 330 — (4 ) (1,347 ) 8,650 — (115 ) (5,440 ) \n Restructuring Charges ((2)) (65 ) — — (377 ) — — — — (2,455 ) — — (2,333 ) \n Share-based Compensation Expense 0 (301 ) (218 ) (899 ) — — — — — — — (4,032 ) \n Executive Related One-Time Costs ((3)) — — — (5,362 ) — — — — — — — — \n Total Adjustments $ 10,447 $ (301 ) $ (218 ) $ (47,928 ) $ 330 $ — $ (4 ) $ (1,529 ) $ 6,195 $ — $ (115 ) $ (32,677 ) \n \n Adjusted $ 243,262 $ 140,508 $ 14,316 $ 50,508 $ 9,239 $ 2,784 $ 682 $ 1,324 $ 269,579 $ 110,871 $ 25,166 $ 45,803 \n % of Revenue 73.6 % 42.5 % 4.3 % 15.3 % 75.9 % 22.9 % 5.6 % 10.9 % 74.1 % 30.5 % 6.9 % 12.6 % \n \n Currency Adjustment (4,389 ) (1,028 ) (10 ) (312 ) N/A N/A N/A N/A N/A N/A N/A N/A \n \n Constant Currency $ 228,426 $ 139,781 $ 14,524 $ 98,124 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 70.2 % 42.9 % 4.5 % 30.1 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n Adjusted Constant Currency $ 238,874 $ 139,480 $ 14,305 $ 50,196 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 73.4 % 42.8 % 4.4 % 15.4 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n \n Note: Totals may not sum due to rounding. \n ((1))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((2))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((3))Non-recurring expenses in connection with the management of certain executive matters. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Three Months Ended June 30, 2026 Six Months Ended June 30, 2026 Period from June 25, 2025 through June 30, 2025 Period from March 30, 2025 through June 24, 2025 Period from December 29, 2024 through June 24, 2025 \n \n \n \n Net Income (Loss) $ 14,074 $ (37,926 ) $ 1,254 $ 1,190,688 $ 1,118,103 \n Net Income (Loss) Margin 8.7 % (11.5 %) 10.3 % 672.7 % 307.5 % \n \n Interest 11,588 23,064 923 11,061 38,664 \n Taxes (11,155 ) (332 ) (523 ) (20,906 ) 1,669 \n Depreciation and Amortization Expenses 25,916 51,802 1,681 7,287 14,201 \n Share-based Compensation Expense 732 1,418 — 3,173 4,032 \n EBITDA $ 41,155 $ 38,026 $ 3,335 $ 1,191,303 $ 1,176,669 \n EBITDA Margin 25.4 % 11.5 % 27.4 % 673.1 % 323.6 % \n \n Franchise Rights Acquired Impairments ((1)) — — — — 27,549 \n Reorganization Items, net ((2)) — — — (1,143,918 ) (1,143,918 ) \n Gain on Extinguishment of Debt ((3)) (4,612 ) (4,612 ) — — — \n Transaction Costs ((4)) — — 182 10,049 20,873 \n Restructuring Charges ((5)) (156 ) 313 — (1,094 ) (122 ) \n Executive Related One-Time Costs ((6)) 3,798 5,362 — — — \n Other ((7)) (421 ) (1,158 ) 932 4,478 6,685 \n Adjusted EBITDA $ 39,764 $ 37,931 $ 4,449 $ 60,818 $ 87,736 \n Adjusted EBITDA Margin 24.5 % 11.5 % 36.6 % 34.4 % 24.1 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The Company's franchise rights acquired impairment charge related to its United States unit of account. \n ((2))The net reorganization gain related to the Company's emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments. \n ((3))Gain on extinguishment of debt consists of the Company's voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par. \n ((4))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((5))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((6))Non-recurring expenses in connection with the management of certain executive matters. \n ((7))Primarily consists of the impact of foreign exchange gains and losses. \n \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4Srl03","title":"Weight Watchers Announces Second Quarter 2026 Results","author":"Globe Newswire","ticker":"WW","created":"2026-08-05T20:01:03.989Z","tickers":["WW"],"exchange":"NASDAQ","article_body":"Total End of Period Subscribers of 2.5 million; End of Period Clinical\nSubscribers of 197 thousand, up 55.7% year-over-year\n\nCore+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year,\nreflecting third consecutive quarter of sequential growth\n\nRevenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up\n30.4% year-over-year\n\nReaffirms Full Year 2026 Financial Guidance\n\nNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq:\nWW) (“Weight Watchers” or the “Company”), the global leader in\nscience-backed weight management, today announced its results for the second\nquarter of 2026 ended June 30, 2026(1) in this Earnings Press Release and a\nShareholder Letter issued today and posted on the Company’s Corporate\nWebsite.\n\n“We view 2026 as a year of focused transition for Weight Watchers, and our\nQ2 results reflect that work taking hold across the business,” said Jon\nVolkmann, Chief Operations Officer and member of the Company’s Interim\nOffice of the Chief Executive. “Core+, our high-value Behavioral tier\ndelivering tailored expert coaching and integrated weight health support,\nposted sequential subscriber growth for the third consecutive quarter,\nunderscoring that members continue to embrace our holistic approach.”\n\n“We are pleased with the continued momentum in Core+, which saw subscriber\ncount grow 13.9% year-over-year and represents a clear signal that interest in\nour Behavioral business is stabilizing while our Clinical business continues\nto grow,” said Felicia DellaFortuna, Chief Financial Officer and member of\nthe Company’s Interim Office of the Chief Executive. “End of Period\nClinical Subscribers grew 55.7% year-over-year, and the sequential stability\nwe saw in subscribers from Q1 to Q2 2026 reflects a deliberate recalibration\nof marketing investment following elevated peak season spend. We are\nreaffirming our full-year 2026 Revenue and Adjusted EBITDA(2) guidance. With a\nbusiness that remains cash accretive and generated positive operating cash\nflow in Q2, we have confidence in our ability to continue building momentum\ninto 2027 and beyond.”\n\nQ2 Business Updates\n* Q2 2026 Clinical Subscription Revenue grew 30.4% year-over-year and End of\nPeriod Clinical Subscribers grew 55.7% year-over-year, despite lapping\nsignificant prior-year growth in Q2 2025 from the Company’s former\ncompounded semaglutide offering. End of Period Clinical Subscribers were flat\ncompared to Q1 2026, as the Company strategically recalibrated its Clinical\nmarketing investment following elevated spend in Q1 2026.\n* Core+ represented 541 thousand End of Period Subscribers at the end of Q2\n2026, up 13.9% from Q2 2025, representing the third consecutive quarter of\nsequential growth in the Company’s higher-value Behavioral tier.\n* Q2 Monthly Subscription Revenue Per Average Subscriber (ARPU) increased\n10.2% year-over-year, driven by the continued mix shift towards Clinical.\n* Q2 Gross Margin was 70.3%. Q2 Adjusted Gross Margin(2) was 73.6%, which\nremained near record highs, reflecting continued operational discipline across\nthe Company’s portfolio.\n* Marketing expense was $47.9 million or 29.5% of Revenue, declining from\n$92.9 million in Q1 2026 as the Company moved past peak season and rebalanced\ninvestment across its business lines.\n* Q2 Net Income was $14.1 million, which reflects higher depreciation and\namortization related to Fresh Start Accounting(1). Q2 Adjusted EBITDA(2) was\n$39.8 million.\nBalance Sheet and Liquidity Updates\n* Cash and Cash Equivalents balance as of June 30, 2026 was $101.5 million.\n* Operating activities generated $24.3 million of cash in Q2 2026, reflecting\nthe cash-generative nature of the Weight Watchers business and continued\ncommitment to maintaining a strong liquidity position as the Company executes\nits strategic priorities.\n* In Q2 2026, the Company prepaid $36.8 million in cash to reduce the\nprincipal amount of its outstanding term loan. The prepayment was comprised of\nthe following two components: * In June 2026, $26.8 million in aggregate\nprincipal amount of prepayment from the annual cash sweep; and\n* In May 2026, $10.0 million as part of the voluntary solicitation, which was\nfully subscribed at 68.5% of par.\nAs a result of these actions, the Company reduced the aggregate principal\namount of its outstanding term loan by $41.4 million and reduced its\nannualized interest expense by approximately $4 million(3).\n\n2026 Guidance\n\nThe Company reaffirms its previously provided guidance for the year ending\nDecember 31, 2026.\n* Revenue guidance of $620 million to $635 million.\n* Adjusted EBITDA(2) guidance of $105 million to $115 million.\nSecond Quarter 2026 Conference Call and Webcast\n\nThe Company has scheduled a conference call today at 5:00 p.m. ET to discuss\nresults. The webcast of the conference call will be available on the\nCompany’s corporate website, corporate.ww.com, under Events and\nPresentations. A replay of the webcast will be available on this site for at\nleast 90 days.\n\n(1)Fresh Start Accounting and Predecessor and Successor Periods\n\nIn connection with the Company’s emergence from its financial reorganization\nprocess on June 24, 2025, the Company applied fresh start accounting which\nresulted in Successor and Predecessor financial statement presentation.\nReferences to “Successor” relate to the Company’s operations for the\nthree and six months ended June 30, 2026 and the period from June 25, 2025\nthrough December 31, 2025. References to “Predecessor” relate to the\nCompany’s operations for the periods from March 30, 2025 through June 24,\n2025 and December 29, 2024 through June 24, 2025. Accordingly, the\nconsolidated financial statements after June 24, 2025 are not comparable with\nthe consolidated financial statements as of or prior to that date.\n\n(2)Statement regarding Non-GAAP Financial Measures\n\nTo supplement the Company’s consolidated results presented in accordance\nwith accounting principles generally accepted in the United States\n(“GAAP”), the Company has disclosed non-GAAP financial measures of\noperating results that exclude or adjust certain items. The Company presents\nin this release non-GAAP financial measures, including earnings before\ninterest, taxes, depreciation and amortization expenses and share-based\ncompensation expense (“EBITDA”); and for each period presented, EBITDA\nadjusted, as applicable, for (a) goodwill and other indefinite-lived\nintangible asset impairments, (b) reorganization items, net related to the\nCompany’s emergence from its Chapter 11 financial reorganization, (c) gain\non extinguishment of debt, (d) transaction costs related to strategic\nalternatives and the Company’s Chapter 11 financial reorganization, (e) net\nrestructuring charges associated with the previously disclosed 2025, 2024, and\n2023 restructuring plans, (f) non-recurring expenses in connection with the\nmanagement of certain executive matters, and (g) other items such as the\nimpact of foreign exchange gains and losses as indicated in the\nreconciliations below that management believes are not indicative of ongoing\noperations (“Adjusted EBITDA”). The Company also presents gross profit,\ngross margin, marketing expenses, selling, general and administrative\nexpenses, and product development expenses on a non-GAAP basis that adjusts\nfor similar items, as further indicated in the reconciliations below.\n\nAs exchange rates are an important factor in understanding period-to-period\ncomparisons, the Company believes in certain cases the presentation of results\non a constant currency basis in addition to reported results helps improve\ninvestors’ ability to understand the Company’s operating results and\nevaluate the Company’s performance in comparison to prior periods. Constant\ncurrency information compares results between periods as if exchange rates had\nremained constant period-over-period. The Company uses results on a constant\ncurrency basis as one measure to evaluate the Company’s performance. In this\npress release, the Company calculates constant currency by calculating\ncurrent-year results using prior-year foreign currency exchange rates. The\nCompany generally refers to such amounts calculated on a constant currency\nbasis as excluding or adjusting for the impact of foreign currency or being on\na constant currency basis. These results should be considered in addition to,\nnot as a substitute for, results reported in accordance with GAAP and are not\nmeant to be considered in isolation. Results on a constant currency basis, as\nthe Company presents them, may not be comparable to similarly titled measures\nused by other companies and are not measures of performance presented in\naccordance with GAAP.\n\nManagement believes these non-GAAP financial measures provide useful\nsupplemental information to investors regarding the performance of the\nCompany’s business and are useful for period-over-period comparisons of the\nperformance of the Company’s business. While the Company believes that these\nnon-GAAP financial measures are useful in evaluating the Company’s business,\nthis information should be considered as supplemental in nature and is not\nmeant to be considered in isolation or as a substitute for the related\nfinancial information prepared in accordance with GAAP. In addition, these\nnon-GAAP financial measures may not be the same as similarly titled measures\nreported by other companies. See “Reconciliation of Non-GAAP Financial\nMeasures” in this release and reconciliations, if any, included elsewhere in\nthis release for a reconciliation of the non-GAAP financial measures to the\nmost directly comparable GAAP measures.\n\nA reconciliation of the forward-looking full year Adjusted EBITDA outlook to\nnet income cannot be provided without unreasonable effort because of the\ninherent difficulty of accurately forecasting the occurrence and financial\nimpact of the various adjusting items necessary for such reconciliation that\nhave not yet occurred, are out of the Company’s control, or cannot be\nreasonably predicted. For the same reasons, the Company is unable to assess\nthe probable significance of the unavailable information, which could have a\nmaterial impact on its future GAAP financial results.\n\n(3)The interest rate in effect for the term loan as of June 30, 2026 was\n10.53%.\n\nDefinitions\n\n“Behavioral” business refers to providing subscriptions to the Company’s\ndigital product offerings with the option to add on unlimited access to the\nCompany’s workshops.\n\n“Clinical” business refers to providing subscriptions to the Company’s\nclinical product offerings provided by Weight Watchers Clinic and third\nparties combined with the Company’s digital subscription product offerings\nand unlimited access to the Company’s workshops.\n\n“Revenue” - “Subscription Revenue” consists of the aggregate of: (a)\n“Behavioral Subscription Revenue”, the fees associated with subscriptions\nfor the Company’s Behavioral offerings; and (b) “Clinical Subscription\nRevenue”, the fees associated with subscriptions for the Company’s\nClinical offerings. In addition, “Other Revenue” consists of revenue from\nlicensing, franchise fees with respect to commitment plans and royalties,\npublishing and other revenue. “Revenue” consists of the aggregate of\nSubscription Revenue and Other Revenue.\n\n“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers\nand Clinical subscribers who participate in recurring bill programs in\nCompany-owned operations. The “Incoming Subscribers” metric reports\nSubscribers in Company-owned operations at a given period start. Recruitment\nand retention are key drivers for this metric. Management utilizes this metric\nto monitor changes in the subscriber base which directly impacts the\nCompany’s revenue growth and trends.\n\n“End of Period Subscribers” - The “End of Period Subscribers” metric\nreports Subscribers in Company-owned operations at a given period end.\nRecruitment and retention are key drivers for this metric. Management utilizes\nthis metric to monitor changes in the subscriber base which directly impacts\nthe Company’s revenue growth and trends.\n\n“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The\n“Monthly Subscription Revenue Per Average Subscriber” metric reports the\nmonthly fees associated with subscriptions for the Company’s offerings\ndivided by the Average Subscriber for its businesses. Monthly Subscription\nRevenue for both quarterly and year-to-date periods for each respective\nbusiness are calculated as Subscription Revenue divided by the number of\nmonths in the respective quarterly or year-to-date period. The “Average\nSubscriber” for quarterly periods for each respective business is the\naverage of its Incoming Subscribers and End of Period Subscribers for the\nrespective quarterly period. The “Average Subscriber” for year-to-date\nperiods for each respective business is the average of its Incoming\nSubscribers at the beginning of the fiscal year and its End of Period\nSubscribers for each quarter end within the respective year-to-date period.\nManagement utilizes this metric to consider revenue growth and trends on a per\nsubscriber basis.\n\nAbout Weight Watchers\nWeight Watchers is the global leader in science-backed weight management,\noffering an integrated support system built for the GLP-1 era that combines\nscientific expertise, medication, cutting-edge technology, and human\nconnection. With more than 60 years of experience, Weight Watchers is the most\nstudied commercial weight management program in the world, delivered through\nits No. 1 U.S. doctor-recommended weight-loss program. Its holistic,\npersonalized approach also includes U.S.-based clinical interventions and\naccess to GLP-1 medications when clinically appropriate, and a global network\nof coaches and community support. Since 1963, the company has led with science\nto deliver its members the personalized support they need to reach and sustain\ntheir goals. Members can access these solutions directly, or through Weight\nWatchers for Business’ full-spectrum platform for employers, health plans,\nand payers. In a landscape crowded with contradictory advice, isolating apps,\nand one-size-fits-all solutions, Weight Watchers offers a proven path forward\nthat is rooted in research, grounded in empathy and designed to help every\nmember feel better in their body and live a longer, healthier life. For more\ninformation, visit weightwatchers.com.\n\nThis press release includes “forward-looking statements,” within the\nmeaning of Section 27A of the Securities Act of 1933, as amended, and Section\n21E of the Securities Exchange Act of 1934, as amended, including, in\nparticular, any statements about the Company’s plans, strategies,\nobjectives, initiatives, and prospects. The Company generally uses the words\n“may,” “will,” “could,” “expect,” “anticipate,”\n“believe,” “estimate,” “plan,” “intend,” “aim” and similar\nexpressions in this press release to identify forward-looking statements. The\nCompany bases these forward-looking statements on its current views with\nrespect to future events and financial performance. Actual results could\ndiffer materially from those projected in the forward-looking statements.\nThese forward-looking statements are subject to risks, uncertainties and\nassumptions, including, among other things: the Company's recent emergence\nfrom bankruptcy, which could adversely affect its business and relationships\nand subjects us to risks and uncertainties; competition from other weight\nmanagement and health and wellness industry participants or the development of\nmore effective or more favorably perceived weight management methods; the\nCompany's failure to continue to retain and grow its subscriber base; the\nCompany's ability to be a leader in the rapidly evolving and increasingly\ncompetitive clinical weight management and weight loss market; the Company's\nability to continue to develop new, innovative services and products and\nenhance its existing services and products or the failure of its services,\nproducts or brands to continue to appeal to the market, or its ability to\nsuccessfully expand into new channels of distribution or respond to consumer\ntrends or sentiment; the Company's ability to successfully implement strategic\ninitiatives; the effectiveness and efficiency of its advertising and marketing\nprograms across multiple platforms, including digital marketing and social\nmedia platforms; the impact on the Company's reputation of actions taken by\nits franchisees, licensees, suppliers, affiliated provider entities, PCs’\nhealthcare professionals, and other partners; the recognition of asset\nimpairment charges; the loss of key personnel, strategic partners or\nconsultants or failure to effectively manage and motivate the Company's\nworkforce; the Company’s chief executive officer transition, and its ability\nto appoint a new chief executive officer with the required level of experience\nand expertise in a timely manner; the Company's ability to successfully make\nacquisitions or enter into collaborations or joint ventures, including its\nability to successfully integrate, operate or realize the anticipated benefits\nof such businesses; uncertainties related to a downturn in general economic\nconditions or consumer confidence, including as a result of the existing\ninflationary environment, changes in tariffs and escalating trade tensions,\nrising interest rates, the potential impact of political and social unrest and\nincreased volatility in the credit and capital markets; the seasonal nature of\nthe Company's business; the Company's failure to maintain effective internal\ncontrol over financial reporting; the impact of events that impede accessing\nresources or discourage or impede people from gathering with others; the early\ntermination by us of leases; the inability to renew certain of the Company's\nlicenses, or the inability to do so on terms that are favorable to us; the\ndependence of the Company's payments system on third-party service providers;\nthe impact of the Company's exposure to variable rate indebtedness; the\nability to generate sufficient cash to service the Company's debt and satisfy\nits other liquidity requirements; uncertainties regarding the satisfactory\noperation of the Company's technology or systems; the impact of data security\nbreaches and other malicious acts or privacy concerns, including the costs of\ncompliance with evolving privacy laws and regulations; the Company's ability\nto successfully integrate and use artificial intelligence in its business; the\nCompany's ability to enforce its intellectual property rights both\ndomestically and internationally, as well as the impact of its involvement in\nany claims related to intellectual property rights; the impact of existing and\nfuture laws and regulations; risks related to the Company's exposure to\nextensive and complex healthcare laws and regulations; the outcomes of\nlitigation or regulatory actions; risks and uncertainties associated with the\nCompany's international operations, including regulatory, economic, political,\nsocial, intellectual property, and foreign currency risks, which risks may be\nexacerbated as a result of war and terrorism; the Company's ability to engage\nin share repurchases and pay cash dividends in the foreseeable future; risks\nrelated to the actions of activist shareholders and anti-takeover provisions\nin the Company's articles of incorporation and bylaws; risks related to the\nactions of the Company's shareholders and the exclusive forum provisions in\nits articles of incorporation; the possibility that the Company could fail to\nmaintain the listing of the Company's common stock on Nasdaq; and other risks\nand uncertainties, including those included in this press release and those\ndetailed from time to time in the Company’s periodic reports filed with the\nSecurities and Exchange Commission (the “SEC”) (which are available on the\nSEC’s EDGAR database at www.sec.gov and via the Company’s website at\ncorporate.ww.com). You should not put undue reliance on any forward-looking\nstatements. You should understand that many important factors, including those\ndiscussed herein, could cause the Company’s results to differ materially\nfrom those expressed or suggested in any forward-looking statement. Except as\nrequired by law, the Company does not undertake any obligation to update or\nrevise these forward-looking statements to reflect new information or events\nor circumstances that occur after the date of this press release or to reflect\nthe occurrence of unanticipated events or otherwise. Readers are advised to\nreview the Company’s filings with the SEC (which are available on the\nSEC’s EDGAR database at www.sec.gov and via the Company’s website at\ncorporate.ww.com).\n\nFor investor inquiries, please contact:\nAnna Kate Heller \nWeightWatchers@icrinc.com\n\nFor media inquiries, please contact:\nMelissa Garbayo\nmelissa.garbayo@ww.com\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED BALANCE SHEETS \n (IN THOUSANDS) \n UNAUDITED \n \n Successor \n June 30, December 31, \n 2026 2025 \n ASSETS \n CURRENT ASSETS \n Cash and cash equivalents $ 101,497 $ 160,279 \n Restricted cash 5,796 6,298 \n Receivables (net of allowances: June 30, 2026 - $1,985 and December 31, 2025 - $1,651) 15,923 16,378 \n Prepaid income taxes 6,573 8,097 \n Prepaid marketing and advertising 3,079 9,275 \n Prepaid expenses and other current assets 14,017 13,277 \n TOTAL CURRENT ASSETS 146,885 213,604 \n Property and equipment, net 6,886 8,115 \n Operating lease assets 2,148 2,933 \n Goodwill 199,910 200,135 \n Other intangible assets, net 453,289 490,664 \n Deferred income taxes 16,068 16,482 \n Other noncurrent assets 15,256 14,825 \n TOTAL ASSETS $ 840,442 $ 946,758 \n LIABILITIES AND EQUITY \n CURRENT LIABILITIES \n Portion of operating lease liabilities due within one year $ 991 $ 1,260 \n Accounts payable 22,537 9,212 \n Salaries and wages payable 20,366 34,375 \n Accrued marketing and advertising 12,238 22,985 \n Accrued interest 867 1,084 \n Other accrued liabilities 21,527 23,049 \n Income taxes payable 2,333 6,006 \n Deferred revenue 25,215 28,565 \n TOTAL CURRENT LIABILITIES 106,074 126,536 \n Long-term debt, net 423,995 465,466 \n Long-term operating lease liabilities 1,325 1,893 \n Deferred income taxes 29,858 34,021 \n Other noncurrent liabilities 540 771 \n TOTAL LIABILITIES 561,792 628,687 \n EQUITY \n Successor common stock, $0 par value; 1,000,000 shares authorized; 9.999 shares issued at June 30, 2026 and 9,992 shares issued at December 31, 2025 379,690 378,777 \n Accumulated deficit (100,021 ) (62,095 ) \n Accumulated other comprehensive (loss) income (1,019 ) 1,389 \n TOTAL EQUITY 278,650 318,071 \n TOTAL LIABILITIES AND TOTAL EQUITY $ 840,442 $ 946,758 \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF OPERATIONS \n (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) \n UNAUDITED \n \n Successor Predecessor \n Three Months Ended Period from Period from \n June 30, 2026 June 25, 2025 March 30, 2025 \n through June 30, 2025 through June 24, 2025 \n \n \n Subscription revenue, net ((1)) $ 161,392 $ 12,078 $ 175,773 \n Other revenue, net ((2)) 932 89 1,224 \n Revenue, net 162,324 12,167 176,997 \n Cost of subscription revenue ((3)) 48,015 3,258 46,439 \n Cost of other revenue 167 — 50 \n Cost of revenue 48,182 3,258 46,489 \n Gross profit 114,142 8,909 130,508 \n Marketing expenses 47,875 2,784 32,093 \n Product development expenses 6,441 686 14,160 \n Selling, general and administrative expenses 50,352 2,853 42,851 \n Operating income 9,474 2,586 41,404 \n Reorganization items, net — — (1,143,918 ) \n Interest expense 11,588 923 11,061 \n Gain on extinguishment of debt (4,612 ) — — \n Other (income) expense, net (421 ) 932 4,478 \n Income before income taxes 2,919 731 1,169,782 \n Benefit from income taxes (11,155 ) (523 ) (20,906 ) \n Net income $ 14,074 $ 1,254 $ 1,190,688 \n \n Earnings per share \n Basic $ 1.41 $ 0.13 $ 14.81 \n Diluted $ 1.41 $ 0.13 $ 14.67 \n \n Weighted average common shares outstanding \n Basic 9,999 9,987 80,419 \n Diluted 10,001 9,987 81,165 \n \n \n Note: Totals may not sum due to rounding. \n ((1) )“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. \n ((2))“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n ((3))“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF OPERATIONS \n (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS) \n UNAUDITED \n \n Successor Predecessor \n Six Months Ended Period from Period from \n June 30, 2026 June 25, 2025 December 29, 2024 \n through June 30, 2025 through June 24, 2025 \n \n \n Subscription revenue, net ((1)) $ 328,749 $ 12,078 $ 360,953 \n Other revenue, net ((2)) 1,836 89 2,615 \n Revenue, net 330,585 12,167 363,568 \n Cost of subscription revenue ((3)) 97,460 3,258 100,026 \n Cost of other revenue 310 — 158 \n Cost of revenue 97,770 3,258 100,184 \n Gross profit 232,815 8,909 263,384 \n Marketing expenses 140,809 2,784 110,871 \n Product development expenses 14,534 686 25,281 \n Selling, general and administrative expenses 98,436 2,853 78,480 \n Franchise rights acquired impairments — — 27,549 \n Operating (loss) income (20,964 ) 2,586 21,203 \n Reorganization items, net — — (1,143,918 ) \n Interest expense 23,064 923 38,664 \n Gain on extinguishment of debt (4,612 ) — — \n Other (income) expense, net (1,158 ) 932 6,685 \n (Loss) income before income taxes (38,258 ) 731 1,119,772 \n (Benefit from) provision for income taxes (332 ) (523 ) 1,669 \n Net (loss) income $ (37,926 ) $ 1,254 $ 1,118,103 \n \n (Net loss) earnings per share \n Basic $ (3.79 ) $ 0.13 $ 13.93 \n Diluted $ (3.79 ) $ 0.13 $ 13.80 \n \n Weighted average common shares outstanding \n Basic 9,998 9,987 80,271 \n Diluted 9,998 9,987 80,998 \n \n \n Note: Totals may not sum due to rounding. \n ((1) )“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. \n ((2))“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n ((3))“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n CONSOLIDATED STATEMENTS OF CASH FLOWS \n (IN THOUSANDS) \n UNAUDITED \n \n Successor Predecessor \n Six Months Ended Period from Period from \n June 30, 2026 June 25, 2025 December 29, 2024 \n through June 30, 2025 through June 24, 2025 \n \n \n Operating activities: \n Net (loss) income $ (37,926 ) $ 1,254 $ 1,118,103 \n Adjustments to reconcile net (loss) income to cash (used for) provided by operating activities: \n Depreciation and amortization 51,802 1,681 14,201 \n Amortization of deferred financing costs and debt (premium) discount, net (51 ) — 1,766 \n Impairment of franchise rights acquired — — 27,549 \n Impairment of intangible and long-lived assets 3 — 97 \n Share-based compensation expense 840 — 4,032 \n Deferred tax (benefit) provision (4,259 ) — 26,232 \n Allowance for doubtful accounts 27 — (1,131 ) \n Foreign currency exchange rate (gain) loss (1,059 ) 933 6,717 \n Non-cash reorganization items, net — — (1,176,532 ) \n Gain on extinguishment of debt (4,612 ) — — \n Changes in cash due to: \n Receivables 227 466 4,280 \n Prepaid expenses 6,978 586 (31,281 ) \n Accounts payable 12,357 406 (8,237 ) \n Accrued liabilities (26,171 ) 6,178 15,084 \n Deferred revenue (3,178 ) 47 (2,914 ) \n Other long term assets and liabilities, net (599 ) — (2,234 ) \n Income taxes (3,654 ) (43 ) (30,155 ) \n Cash (used for) provided by operating activities (9,275 ) 11,508 (34,423 ) \n Investing activities: \n Capital expenditures — — (87 ) \n Capitalized software and website development expenditures (11,935 ) (188 ) (6,253 ) \n Other items, net — — (1 ) \n Cash used for investing activities (11,935 ) (188 ) (6,341 ) \n Financing activities: \n Borrowings on revolving credit facility — — 171,341 \n Financing costs — — (1,298 ) \n Payments on long-term debt (36,808 ) — — \n Taxes paid related to net share settlement of equity awards — — (145 ) \n Cash paid for acquisitions — — (16,000 ) \n Cash (used for) provided by financing activities (36,808 ) — 153,898 \n Effect of exchange rate changes on cash and cash equivalents and restricted cash (1,266 ) 544 3,966 \n Net (decrease) increase in cash and cash equivalents and restricted cash (59,284 ) 11,864 117,100 \n Cash and cash equivalents and restricted cash, beginning of period 166,577 173,620 56,520 \n Cash and cash equivalents and restricted cash, end of period $ 107,293 $ 185,484 $ 173,620 \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Variance \n Successor 2026 vs 2025 Combined 2026 Constant Currency vs 2025 Combined \n Three Months Ended Three Months Ended \n June 30, 2026 June 30, 2025 \n GAAP Constant Currency Combined ((1)) \n \n Selected Financial Data \n Revenue ((2)) $ 162,324 $ 161,523 $ 189,163 (14.2 %) (14.6 %) \n Behavioral Subscription Revenue ((3)) $ 121,486 $ 120,689 $ 157,258 (22.7 %) (23.3 %) \n Clinical Subscription Revenue ((4)) $ 39,906 $ 39,908 $ 30,593 30.4 % 30.4 % \n Subscription Revenue ((5)) $ 161,392 $ 160,597 $ 187,851 (14.1 %) (14.5 %) \n Other Revenue ((6)) $ 932 $ 926 $ 1,312 (29.0 %) (29.4 %) \n \n \n Note: Totals may not sum due to rounding. \n ((1))These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented. \n ((2))“Revenue” consists of the aggregate of Subscription Revenue and Other Revenue. \n ((3))“Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings. \n ((4))“Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings. \n ((5))“Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue. \n ((6))“Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Variance \n Successor 2026 vs 2025 Combined 2026 Constant Currency vs 2025 Combined \n Six Months Ended June 30, 2026 Six Months Ended June 30, 2025 \n GAAP Constant Currency Combined ((1)) \n \n Selected Financial Data \n Revenue ((2)) $ 330,585 $ 325,531 $ 375,735 (12.0 %) (13.4 %) \n Behavioral Subscription Revenue ((3)) $ 250,010 $ 245,006 $ 312,981 (20.1 %) (21.7 %) \n Clinical Subscription Revenue ((4)) $ 78,739 $ 78,741 $ 60,051 31.1 % 31.1 % \n Subscription Revenue ((5)) $ 328,749 $ 323,746 $ 373,032 (11.9 %) (13.2 %) \n Other Revenue ((6)) $ 1,836 $ 1,784 $ 2,703 (32.1 %) (34.0 %) \n \n \n Note: Totals may not sum due to rounding. \n ((1))These amounts combine the revenue of the Successor and Predecessor periods for comparability purposes. Although the Successor and Predecessor have a different accounting basis due to the application of fresh start accounting, none of the fresh start accounting adjustments impact revenue. Therefore, the combined revenue amounts presented are consistent with a pro forma presentation under Article 11 of Regulation S-X as if fresh start accounting was applied at the beginning of the first period presented. \n ((2))“Revenue” consists of the aggregate of Subscription Revenue and Other Revenue. \n ((3))“Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings. \n ((4))“Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings. \n ((5))“Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue. \n ((6))“Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n OPERATIONAL STATISTICS \n (IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER) \n UNAUDITED \n \n Successor Combined \n Three Months Ended Three Months Ended \n June 30, 2026 June 30, 2025 Variance Variance \n (Constant Currency) (Constant Currency) \n Incoming Subscribers ((1)) \n Incoming Behavioral Subscribers 2,463 N/A 3,299 (25.4 %) N/A \n Incoming Clinical Subscribers 197 N/A 135 45.9 % N/A \n Incoming Subscribers 2,659 N/A 3,434 (22.6 %) N/A \n \n End of Period Subscribers ((2)) \n End of Period Behavioral Subscribers 2,291 N/A 3,040 (24.6 %) N/A \n End of Period Clinical Subscribers 197 N/A 127 55.7 % N/A \n End of Period Subscribers 2,489 N/A 3,167 (21.4 %) N/A \n \n Monthly Subscription Revenue Per Average Subscriber ( (3)) \n Monthly Behavioral Subscription Revenue Per Average Subscriber $ 17.04 $ 16.92 $ 16.54 3.0 % 2.3 % \n Monthly Clinical Subscription Revenue Per Average Subscriber $ 67.55 $ 67.55 $ 78.00 (13.4 %) (13.4 %) \n Monthly Subscription Revenue Per Average Subscriber $ 20.90 $ 20.80 $ 18.97 10.2 % 9.6 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start. \n ((2))The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end. \n ((3))The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers \n and End of Period Subscribers for the respective quarterly period. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n OPERATIONAL STATISTICS \n (IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER) \n UNAUDITED \n \n Successor Combined \n Six Months Ended Six Months Ended \n June 30, 2026 June 30, 2025 Variance Variance \n (Constant Currency) (Constant Currency) \n Incoming Subscribers ((1)) \n Incoming Behavioral Subscribers 2,631 N/A 3,244 (18.9 %) N/A \n Incoming Clinical Subscribers 130 N/A 92 41.9 % N/A \n Incoming Subscribers 2,761 N/A 3,336 (17.2 %) N/A \n \n End of Period Subscribers ((2)) \n End of Period Behavioral Subscribers 2,291 N/A 3,040 (24.6 %) N/A \n End of Period Clinical Subscribers 197 N/A 127 55.7 % N/A \n End of Period Subscribers 2,489 N/A 3,167 (21.4 %) N/A \n \n Monthly Subscription Revenue Per Average Subscriber ( (3)) \n Monthly Behavioral Subscription Revenue Per Average Subscriber $ 16.91 $ 16.57 $ 16.33 3.6 % 1.5 % \n Monthly Clinical Subscription Revenue Per Average Subscriber $ 75.13 $ 75.13 $ 85.01 (11.6 %) (11.6 %) \n Monthly Subscription Revenue Per Average Subscriber $ 20.76 $ 20.45 $ 18.77 10.6 % 8.9 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start. \n ((2))The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end. \n ((3))The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for year-to-date periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective year-to-date period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming \n Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. \n \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Period from Period from \n Three Months Ended June 25, 2025 March 30, 2025 \n June 30, 2026 through June 30, 2025 through June 24, 2025 \n Selling, Selling, Selling, \n Product General, and Product General, and Product General, and \n Gross Marketing Development Administrative Gross Marketing Development Administrative Gross Marketing Development Administrative \n Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses \n \n GAAP $ 114,142 $ 47,875 $ 6,441 $ 50,352 $ 8,909 $ 2,784 $ 686 $ 2,853 $ 130,508 $ 32,093 $ 14,160 $ 42,851 \n % of Revenue 70.3 % 29.5 % 4.0 % 31.0 % 73.2 % 22.9 % 5.6 % 23.4 % 73.7 % 18.1 % 8.0 % 24.2 % \n \n Adjustments: \n Transaction Costs ((1)) $ — $ — $ — $ — $ — $ — $ — $ (182 ) $ — $ — $ — $ (10,049 ) \n Depreciation and Amortization Expenses 5,331 — — (20,585 ) 330 — (4 ) (1,347 ) 4,147 — (54 ) (3,086 ) \n Restructuring Charges ((2)) — — — 156 — — — — (2,071 ) — — (977 ) \n Share-based Compensation Expense 0 (160 ) (109 ) (463 ) — — — — — — — (3,171 ) \n Executive Related One-Time Costs ((3)) — — — (3,798 ) — — — — — — — — \n Total Adjustments $ 5,332 $ (160 ) $ (109 ) $ (24,690 ) $ 330 $ — $ (4 ) $ (1,529 ) $ 2,076 $ — $ (54 ) $ (17,284 ) \n \n Adjusted $ 119,474 $ 47,715 $ 6,332 $ 25,662 $ 9,239 $ 2,784 $ 682 $ 1,324 $ 132,584 $ 32,093 $ 14,106 $ 25,567 \n % of Revenue 73.6 % 29.4 % 3.9 % 15.8 % 75.9 % 22.9 % 5.6 % 10.9 % 74.9 % 18.1 % 8.0 % 14.4 % \n \n Currency Adjustment (698 ) (41 ) 0 (51 ) N/A N/A N/A N/A N/A N/A N/A N/A \n \n Constant Currency $ 113,444 $ 47,834 $ 6,441 $ 50,301 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 70.2 % 29.6 % 4.0 % 31.1 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n Adjusted Constant Currency $ 118,775 $ 47,675 $ 6,332 $ 25,610 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 73.5 % 29.5 % 3.9 % 15.9 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n \n Note: Totals may not sum due to rounding. \n ((1))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((2))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((3))Non-recurring expenses in connection with the management of certain executive matters. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Period from Period from \n Six Months Ended June 25, 2025 December 29, 2024 \n June 30, 2026 through June 30, 2025 through June 24, 2025 \n Selling, Selling, Selling, \n Product General, and Product General, and Product General, and \n Gross Marketing Development Administrative Gross Marketing Development Administrative Gross Marketing Development Administrative \n Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses Profit Expenses Expenses Expenses \n \n GAAP $ 232,815 $ 140,809 $ 14,534 $ 98,436 $ 8,909 $ 2,784 $ 686 $ 2,853 $ 263,384 $ 110,871 $ 25,281 $ 78,480 \n % of Revenue 70.4 % 42.6 % 4.4 % 29.8 % 73.2 % 22.9 % 5.6 % 23.4 % 72.4 % 30.5 % 7.0 % 21.6 % \n \n Adjustments: \n Transaction Costs ((1)) $ — $ — $ — $ — $ — $ — $ — $ (182 ) $ — $ — $ — $ (20,873 ) \n Depreciation and Amortization Expenses 10,512 — — (41,290 ) 330 — (4 ) (1,347 ) 8,650 — (115 ) (5,440 ) \n Restructuring Charges ((2)) (65 ) — — (377 ) — — — — (2,455 ) — — (2,333 ) \n Share-based Compensation Expense 0 (301 ) (218 ) (899 ) — — — — — — — (4,032 ) \n Executive Related One-Time Costs ((3)) — — — (5,362 ) — — — — — — — — \n Total Adjustments $ 10,447 $ (301 ) $ (218 ) $ (47,928 ) $ 330 $ — $ (4 ) $ (1,529 ) $ 6,195 $ — $ (115 ) $ (32,677 ) \n \n Adjusted $ 243,262 $ 140,508 $ 14,316 $ 50,508 $ 9,239 $ 2,784 $ 682 $ 1,324 $ 269,579 $ 110,871 $ 25,166 $ 45,803 \n % of Revenue 73.6 % 42.5 % 4.3 % 15.3 % 75.9 % 22.9 % 5.6 % 10.9 % 74.1 % 30.5 % 6.9 % 12.6 % \n \n Currency Adjustment (4,389 ) (1,028 ) (10 ) (312 ) N/A N/A N/A N/A N/A N/A N/A N/A \n \n Constant Currency $ 228,426 $ 139,781 $ 14,524 $ 98,124 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 70.2 % 42.9 % 4.5 % 30.1 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n Adjusted Constant Currency $ 238,874 $ 139,480 $ 14,305 $ 50,196 N/A N/A N/A N/A N/A N/A N/A N/A \n % of Revenue 73.4 % 42.8 % 4.4 % 15.4 % N/A N/A N/A N/A N/A N/A N/A N/A \n \n \n Note: Totals may not sum due to rounding. \n ((1))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((2))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((3))Non-recurring expenses in connection with the management of certain executive matters. \n\n\n\n WW INTERNATIONAL, INC. AND SUBSIDIARIES \n RECONCILIATION OF NON-GAAP FINANCIAL MEASURES \n (IN THOUSANDS, EXCEPT PERCENTAGES) \n UNAUDITED \n \n Successor Predecessor \n Three Months Ended June 30, 2026 Six Months Ended June 30, 2026 Period from June 25, 2025 through June 30, 2025 Period from March 30, 2025 through June 24, 2025 Period from December 29, 2024 through June 24, 2025 \n \n \n \n Net Income (Loss) $ 14,074 $ (37,926 ) $ 1,254 $ 1,190,688 $ 1,118,103 \n Net Income (Loss) Margin 8.7 % (11.5 %) 10.3 % 672.7 % 307.5 % \n \n Interest 11,588 23,064 923 11,061 38,664 \n Taxes (11,155 ) (332 ) (523 ) (20,906 ) 1,669 \n Depreciation and Amortization Expenses 25,916 51,802 1,681 7,287 14,201 \n Share-based Compensation Expense 732 1,418 — 3,173 4,032 \n EBITDA $ 41,155 $ 38,026 $ 3,335 $ 1,191,303 $ 1,176,669 \n EBITDA Margin 25.4 % 11.5 % 27.4 % 673.1 % 323.6 % \n \n Franchise Rights Acquired Impairments ((1)) — — — — 27,549 \n Reorganization Items, net ((2)) — — — (1,143,918 ) (1,143,918 ) \n Gain on Extinguishment of Debt ((3)) (4,612 ) (4,612 ) — — — \n Transaction Costs ((4)) — — 182 10,049 20,873 \n Restructuring Charges ((5)) (156 ) 313 — (1,094 ) (122 ) \n Executive Related One-Time Costs ((6)) 3,798 5,362 — — — \n Other ((7)) (421 ) (1,158 ) 932 4,478 6,685 \n Adjusted EBITDA $ 39,764 $ 37,931 $ 4,449 $ 60,818 $ 87,736 \n Adjusted EBITDA Margin 24.5 % 11.5 % 36.6 % 34.4 % 24.1 % \n \n \n Note: Totals may not sum due to rounding. \n ((1))The Company's franchise rights acquired impairment charge related to its United States unit of account. \n ((2))The net reorganization gain related to the Company's emergence from its Chapter 11 financial reorganization and primarily consisted of the gain on settlement of liabilities subject to compromise and the impacts of fresh start valuation adjustments. \n ((3))Gain on extinguishment of debt consists of the Company's voluntary prepayment in May 2026 of a portion of its New Term Loan Facility at 68.5% of par. \n ((4))Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization. \n ((5))Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan. \n ((6))Non-recurring expenses in connection with the management of certain executive matters. \n ((7))Primarily consists of the impact of foreign exchange gains and losses. \n \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-05T20:01:05.062697614Z","server_sent_at_ms":1785960065062},"received_at":"2026-08-05T20:01:05.218Z","source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339651/0/en/weight-watchers-announces-second-quarter-2026-results.html"},"analysis":{"id":"98953","press_release_id":"109943","analysis_json":{"industry":{"label":"Specialized Consumer Services","sector":"Consumer Discretionary"},"redFlags":["Total revenue declined 14.2% year-over-year","Total subscribers declined year-over-year","Operating under Interim Office of the Chief Executive","Term loan interest rate is 10.53%"],"eventType":"earnings","narrative":"Weight Watchers reported Q2 2026 revenue of $162.3 million, down 14.2% year-over-year, with net income of $14.1 million and EPS of $1.41.\n\nEnd-of-period subscribers totaled 2.5 million, driven by a 55.7% increase in clinical subscribers to 197,000 and a 13.9% rise in Core+ subscribers to 541,000.\n\nThe company reaffirmed its full-year 2026 revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million.\n\nOperating activities generated $24.3 million in cash during the quarter, and the company reduced its outstanding term loan principal by $41.4 million.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"WW's turnaround stabilizes with clinical segment growth, though total revenue and subscriber counts decline."},"keyFigures":{"eps":1.41,"revenue":162300000,"guidance":"Revenue of $620 million to $635 million; Adjusted EBITDA of $105 million to $115 million","revenueYoy":"-14.2%","customDimensions":{"net_income":14100000,"adjusted_ebitda":39800000,"clinical_revenue":39900000,"operating_cash_flow":24300000,"cash_and_equivalents":101500000,"clinical_subscribers":197000,"core_plus_subscribers":541000,"end_of_period_subscribers":2500000,"term_loan_principal_reduction":41400000}},"quotedText":"We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business","namedEntities":{"people":[{"name":"Jon Volkmann","role":"Chief Operations Officer and member of the Interim Office of the Chief Executive"},{"name":"Felicia DellaFortuna","role":"Chief Financial Officer and member of the Interim Office of the Chief Executive"}],"products":["Core+","Clinical","Weight Watchers Clinic"],"companies":[{"name":"WW International, Inc.","ticker":"WW"}],"dollarAmounts":[{"amount":"$162.3 million","context":"Q2 2026 Revenue"},{"amount":"$39.9 million","context":"Q2 2026 Clinical Subscription Revenue"},{"amount":"$14.1 million","context":"Q2 2026 Net Income"},{"amount":"$620 million to $635 million","context":"Full Year 2026 Revenue Guidance"},{"amount":"$105 million to $115 million","context":"Full Year 2026 Adjusted EBITDA Guidance"},{"amount":"$47.9 million","context":"Q2 2026 Marketing expense"},{"amount":"$39.8 million","context":"Q2 2026 Adjusted EBITDA"},{"amount":"$101.5 million","context":"Cash and Cash Equivalents balance as of June 30, 2026"},{"amount":"$24.3 million","context":"Cash generated by operating activities in Q2 2026"},{"amount":"$36.8 million","context":"Cash prepaid to reduce term loan principal in Q2 2026"}]},"materialImpact":{"score":3,"reasoning":"Standard quarterly earnings release featuring mixed metrics with total revenue and subscribers declining year-over-year while high-value clinical segments grow. The company reaffirmed full-year guidance, suggesting stability rather than material upside surprise or deterioration."},"tickerRelevance":{"others":[],"primary":"WW"},"globalImportance":25,"audienceRelevance":45,"eventTypeSecondary":["guidance_update"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"standard_earnings","householdBrandBoost":true}},"event_type":"earnings","event_type_secondary":["guidance_update"],"sentiment":"neutral","material_impact_score":3,"narrative":"Weight Watchers reported Q2 2026 revenue of $162.3 million, down 14.2% year-over-year, with net income of $14.1 million and EPS of $1.41.\n\nEnd-of-period subscribers totaled 2.5 million, driven by a 55.7% increase in clinical subscribers to 197,000 and a 13.9% rise in Core+ subscribers to 541,000.\n\nThe company reaffirmed its full-year 2026 revenue guidance of $620 million to $635 million and Adjusted EBITDA guidance of $105 million to $115 million.\n\nOperating activities generated $24.3 million in cash during the quarter, and the company reduced its outstanding term loan principal by $41.4 million.","key_figures":{"eps":1.41,"revenue":162300000,"guidance":"Revenue of $620 million to $635 million; Adjusted EBITDA of $105 million to $115 million","revenueYoy":"-14.2%","customDimensions":{"net_income":14100000,"adjusted_ebitda":39800000,"clinical_revenue":39900000,"operating_cash_flow":24300000,"cash_and_equivalents":101500000,"clinical_subscribers":197000,"core_plus_subscribers":541000,"end_of_period_subscribers":2500000,"term_loan_principal_reduction":41400000}},"named_entities":{"people":[{"name":"Jon Volkmann","role":"Chief Operations Officer and member of the Interim Office of the Chief Executive"},{"name":"Felicia DellaFortuna","role":"Chief Financial Officer and member of the Interim Office of the Chief Executive"}],"products":["Core+","Clinical","Weight Watchers Clinic"],"companies":[{"name":"WW International, Inc.","ticker":"WW"}],"dollarAmounts":[{"amount":"$162.3 million","context":"Q2 2026 Revenue"},{"amount":"$39.9 million","context":"Q2 2026 Clinical Subscription Revenue"},{"amount":"$14.1 million","context":"Q2 2026 Net Income"},{"amount":"$620 million to $635 million","context":"Full Year 2026 Revenue Guidance"},{"amount":"$105 million to $115 million","context":"Full Year 2026 Adjusted EBITDA Guidance"},{"amount":"$47.9 million","context":"Q2 2026 Marketing expense"},{"amount":"$39.8 million","context":"Q2 2026 Adjusted EBITDA"},{"amount":"$101.5 million","context":"Cash and Cash Equivalents balance as of June 30, 2026"},{"amount":"$24.3 million","context":"Cash generated by operating activities in Q2 2026"},{"amount":"$36.8 million","context":"Cash prepaid to reduce term loan principal in Q2 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T23:02:10.655Z","global_importance":25,"audience_relevance":45,"importance_components":{"tickerTier":"mid-cap","eventGravity":"standard_earnings","householdBrandBoost":true}},"durationMs":331069,"modelName":"glm-4.7"}}